Oral GLP-1 Receptor Agonist Elecoglipron Achieves Up to 11.8% Weight Loss and 7% Blood Sugar Reduction in Phase 2b Trials

June 20, 2026

Medical News Today (citing The Lancet) International

Overview

Once-daily oral GLP-1 receptor agonist elecoglipron demonstrated significant efficacy in its Phase 2b SOLSTICE clinical trial. Obese and overweight adults achieved up to an 11.8% body weight reduction without strict dietary restrictions. Concurrently, type 2 diabetes patients showed an average 7% reduction in blood sugar levels, alongside weight loss benefits. This data strongly supports progression to large-scale Phase 3 trials and offers a convenient oral treatment option for a broader patient population, including those with needle phobia.

In Depth

Key Findings

The novel oral GLP-1 receptor agonist, elecoglipron, has achieved groundbreaking results in its Phase 2b SOLSTICE clinical trial, demonstrating up to an 11.8% significant body weight reduction in obese and overweight adults and a 7% reduction in blood sugar levels for type 2 diabetes patients. These impressive outcomes were attained without stringent dietary or fluid restrictions, signaling a potentially transformative oral therapeutic option for conditions with high unmet medical needs.

Technical / Clinical Details

Elecoglipron functions by activating the Glucagon-like Peptide-1 (GLP-1) receptor, thereby promoting insulin secretion, suppressing glucagon release, and delaying gastric emptying. In the Phase 2b SOLSTICE trial, various dose cohorts of elecoglipron were evaluated against a placebo. The results showed statistically significant improvements in both weight reduction and glycemic control in patients receiving once-daily oral elecoglipron. Specifically, participants experienced an average body weight reduction of up to 11.8% over the study period. Concurrently, type 2 diabetes patients saw their HbA1c levels, a key indicator of long-term blood sugar control, decrease by an average of 7%. The safety profile was also favorable, with reported side effects consistent with those observed with other GLP-1 agonists, primarily gastrointestinal in nature and generally mild to moderate.

Background & Context

Obesity and type 2 diabetes represent a growing global health crisis, necessitating effective and convenient treatment modalities. GLP-1 receptor agonists have emerged as a standard of care due to their high efficacy in both conditions. However, the majority of these therapies are injectable, posing compliance challenges and a barrier for patients with needle phobia. The development of oral GLP-1 medications is a critical advancement to overcome these hurdles and broaden patient access to these highly effective treatments. Elecoglipron’s success positions it with significant competitive potential in this burgeoning market and could influence the development strategies of competitors, such as Eli Lilly’s oral GLP-1 programs.

Strategic Significance & Outlook

The promising Phase 2b results for elecoglipron provide strong justification for advancing to large-scale Phase 3 clinical trials. If long-term efficacy and safety are further validated in these pivotal trials, and subsequently approved, elecoglipron is poised to play a crucial role in the treatment landscape for obesity and type 2 diabetes as a convenient, non-injectable option. This oral GLP-1 drug has the potential to significantly improve patients’ quality of life and address adherence challenges in chronic disease management, and is therefore anticipated to achieve substantial market success.

Source: https://www.medicalnewstoday.com/articles/new-oral-glp-1-drug-lowers-blood-sugar-levels-by-7-in-2-diabetes

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.